Department of Respiratory and Critical Care Medicine, Huzhou Central Hospital, Affiliated Huzhou Hospital, Zhejiang University School of Medicine, 313000, Zhejiang, No. 1558, Third Ring North Road, Huzhou, China.
Scand J Immunol. 2023 Jun;97(6):e13267. doi: 10.1111/sji.13267. Epub 2023 Apr 3.
Mesenchymal stromal/stem cells (MSCs) possess the ability to self-renew and differentiate into other cell types. Because of their anti-inflammatory and immunomodulatory abilities, as well as their more ready availability compared to other stem cell sources, MSCs hold great promise for the treatment of many diseases, such as haematological defects, acute respiratory distress syndrome, autoimmunity, cardiovascular diseases, etc. However, immune rejection remains an important problem. MSCs are considered to have low immunogenicity, but they do not have full immunological privilege. This review analyzes and discusses the safety of MSCs from the perspective of their immunogenicity, with the aim of providing a reference for future research and clinical application.
间充质基质/干细胞（MSCs）具有自我更新和分化为其他细胞类型的能力。由于其抗炎和免疫调节能力，以及与其他干细胞来源相比更容易获得，MSCs 在治疗许多疾病方面具有广阔的前景，如血液学缺陷、急性呼吸窘迫综合征、自身免疫、心血管疾病等。然而，免疫排斥仍然是一个重要的问题。MSCs 被认为具有低免疫原性，但它们没有完全的免疫特权。本综述从免疫原性的角度分析和讨论了 MSCs 的安全性，旨在为未来的研究和临床应用提供参考。
